These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 10972629)

  • 1. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.
    Moyle G
    Clin Ther; 2000 Aug; 22(8):911-36; discussion 898. PubMed ID: 10972629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial toxicity: myths and facts.
    Moyle G
    J HIV Ther; 2004 May; 9(2):45-7. PubMed ID: 15238876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A brief overview of mechanisms of mitochondrial toxicity from NRTIs.
    Kohler JJ; Lewis W
    Environ Mol Mutagen; 2007; 48(3-4):166-72. PubMed ID: 16758472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.
    Kakuda TN
    Clin Ther; 2000 Jun; 22(6):685-708. PubMed ID: 10929917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV and mitochondrial toxicity in children.
    Foster C; Lyall H
    J Antimicrob Chemother; 2008 Jan; 61(1):8-12. PubMed ID: 17999978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy.
    Côté HC
    Antivir Ther; 2005; 10 Suppl 2():M3-11. PubMed ID: 16152702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms.
    Nolan D; Mallal S
    Antivir Ther; 2004 Dec; 9(6):849-63. PubMed ID: 15651744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of reverse transcriptase inhibitors on sperm mitochondrial and genomic DNA in assisted reproduction techniques].
    Sergerie M; Martinet S; Kiffer N; Teulé R; Pasquier C; Bujan L
    Gynecol Obstet Fertil; 2004 Oct; 32(10):841-9. PubMed ID: 15501159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
    De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
    Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity.
    Höschele D
    Toxicol In Vitro; 2006 Aug; 20(5):535-46. PubMed ID: 16406476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy.
    Lewis W
    Antivir Ther; 2005; 10 Suppl 2():M13-27. PubMed ID: 16152703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
    Nolan D; Hammond E; James I; McKinnon E; Mallal S
    Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors.
    Miller RF; Shahmonesh M; Hanna MG; Unwin RJ; Schapira AH; Weller IV
    Antivir Ther; 2003 Jun; 8(3):253-7. PubMed ID: 12924544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature.
    Simdon J; Watters D; Bartlett S; Connick E
    Clin Infect Dis; 2001 Jun; 32(11):1623-7. PubMed ID: 11340535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients.
    Maagaard A; Holberg-Petersen M; Kvittingen EA; Sandvik L; Bruun JN
    HIV Med; 2006 Jan; 7(1):53-8. PubMed ID: 16313293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term complications of nucleoside reverse transcriptase inhibitor therapy.
    Dieterich DT
    AIDS Read; 2003 Apr; 13(4):176-84, 187. PubMed ID: 12741368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients.
    Ciccosanti F; Corazzari M; Soldani F; Matarrese P; Pagliarini V; Iadevaia V; Tinari A; Zaccarelli M; Perfettini JL; Malorni W; Kroemer G; Antinori A; Fimia GM; Piacentini M
    Antivir Ther; 2010; 15(3):377-90. PubMed ID: 20516557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.